PubRank

Chanson J Brumme

Author PubWeight™ 85.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
2 Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2004 4.55
3 Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008 3.48
4 Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 2012 3.35
5 Influence of HLA-C expression level on HIV control. Science 2013 3.27
6 Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol 2008 3.24
7 HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 2008 3.24
8 Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007 2.81
9 Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005 2.42
10 Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol 2008 2.32
11 HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009 2.16
12 HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 2008 1.95
13 Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 2008 1.94
14 Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 2010 1.82
15 Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 2010 1.81
16 Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 2010 1.80
17 Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 2011 1.73
18 Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS 2008 1.67
19 HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 2009 1.54
20 Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet 2009 1.51
21 Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012 1.48
22 Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol 2011 1.45
23 A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007 1.41
24 Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr 2012 1.38
25 Transmission and long-term stability of compensated CD8 escape mutations. J Virol 2008 1.29
26 Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 2012 1.29
27 Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 2011 1.27
28 HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005 1.25
29 A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife 2013 1.19
30 Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med 2010 1.19
31 The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 2008 1.16
32 Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005 1.09
33 Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007 1.08
34 Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology 2013 1.01
35 Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J Immunol 2012 0.98
36 Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol 2012 0.93
37 Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 2014 0.92
38 Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011 0.91
39 CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses 2008 0.86
40 Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob Agents Chemother 2013 0.85
41 Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine. Antimicrob Agents Chemother 2014 0.85
42 Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010. J Acquir Immune Defic Syndr 2014 0.84
43 HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2006 0.84
44 Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Sci Rep 2013 0.82
45 Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antivir Ther 2005 0.80
46 Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1. Clin Infect Dis 2012 0.78
47 Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One 2012 0.78
48 Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. Biochem Biophys Res Commun 2012 0.77
49 No inherent association between minor mutations in HIV protease at baseline and selection of the L90M mutation at the time of the first virological failure. J Infect Dis 2005 0.76
50 Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase. AIDS 2016 0.75
51 Prevalence and clinical impacts of HIV-1 intersubtype recombinants in uganda revealed by a near-full-genome population and deep sequencing approaches. AIDS 2017 0.75